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A B S T R A C T
The study included 20 patients with diabetes mellitus type I (DM I) and 16 with type II (DM II) suffering from
prolipherative diabetic retinopathy (PDR) for which they underwent vitrectomy. The quantity of VEGF and its receptors
in the vitreous of investigated patients were measured by immunoassay and results compared between patients with DM
I and II. The mean levels in the vitreous were significantly higher in diabetics with PDR and diabetes mellitus I (432.2
pg/mL, 1460.4 pg/mL and 1054.6 pg/mL) than in diabetics with PDR and diabetes mellitus II (147.5 pg/mL, 641.4
pg/mL and 448.5 pg/mL) and in control group (63.26 pg/mL). Considering that VEGF, VEGFR1 and VEGFR2 levels
were significantly higher in diabetics with PDR than in controls and that the patients with DM I had higher levels than
with DM II, anti-VEGF therapy might be beneficial for diabetics with PDR, especially those with DM I.
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Introduction
It is known that vascularisation and proliferation
have a main role in complications in patients with pro-
liferative diabetic retinopathy (PDR). We studied the role
of VEGF and its receptors in the development of vascu-
larisation and proliferation in patients with PDR. We de-
termined the quantity of VEGF and its receptors in the
ocular fluids in patients with PDR in DM I and DM II. We
aimed to establish whether VEGF level is increased in
the vitreous of patients with PDR and how it depends on
type of diabetes mellitus (DM I and DM II).
Diabetes mellitus is the most frequent endocrine dis-
ease in developed countries. The disease is estimated to
be present in 2–5% of the world’s population and diabetic
retinopathy is the most frequent cause of legal blindness
in the population of 30–70-year old.
The most difficult and long-lasting complications in
diabetes mellitus are caused by the changes present in
vessels, creating vessel damage and angiopathy in whole
body as well as in the eye1,2.
Physiopathology of diabetic retinopathy
The lesions that characterize diabetic retinopathy are
the results of four main processes: the appearance of mi-
cro-aneurysms, increased vascular permeability, capil-
lary occlusion and fibrous and neovascular prolifera-
tion2–4.
An increase in the number of micro-aneurysms is con-
sidered a risk sign for progression of retinopathy. A fur-
ther sign that indicates an even greater risk of progres-
sion of retinopathy is excessive permeability of the reti-
nal vessels. The lack of perycites compromise nutritional
supply to the endothelial cells and impair, the barrier
function of these cells. Fluid leakage can range from mi-
cro-exudates to the macular edema, which can seriously
reduce vision. Another lesion that can appear in diabetic
retinopathy is capillary occlusion, which gives rise to an
area of retinal ischemia. The resulting ischemia leads to
the proliferation of vessels that seek out new routes to ir-
rigate the affected area. The vessels are fragile and made
up of endothelial cells that proliferate without the bene-
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fit of a consistent basement membrane. Sometimes the
new vessels are surrounded by fibrous tissue, and the
fibrovascular complex adheres to the posterior part of
the vitreous cavity. Traction on the vitreous can rupture
the weak structure of the new vessels and lead to vitre-
ous hemorrhage or even retinal detachment2–6.
Biochemical alterations-first stage
Prolonged hyperglycemia is the key element to all
alterations involved in the development of diabetic re-
tinopathy. High concentrations of blood glucose lead to
changes in cell metabolism such as: polyol pathway acti-
vation, diacylglycerol protein kinase C pathway activa-
tion, stimulation of cellular oxidative stress and changes
in macromolecule structure and function via the forma-
tion of advanced glycation end products (AGEs). These
biochemical alterations account the most of the cellular
lesions that appear in diabetic retinopathy especially in
the endothelium of retinal vessels, which lead to endo-
thelial dysfunction7–9.
Second stage-endothelial dysfunction
Endothelial cells are able to release vascular growth
factors that are important for vascular proliferation, an
important step in the development of diabetic retino-
pathy. Of all the growth factors, vascular endothelial
growth factor (VEGF) is the one most closely related
with retinal vascularisation as it participates in the for-
mation of new vessels that appear after retinal ische-
mia9.
Third stage-failure of retinal vascular function
Deficient antithrombotic function together with stim-
ulation of platelet function may favor ischemic phenom-
ena. These factors lead to a pathophysiological process
that accounts for the many complex morphological le-
sions that appear in patients with diabetes who develop
diabetic retinopathy10.
Therapeutic management of diabetic retinopathy
Development of drugs that prevent the appearance of
diabetic retinopathy (DR) is a fundamental goal in cur-
rent research. Early detection of the initial signs of dia-
betic retinopathy is crucial for the success of preventive
measures.
Intensive control of glycemia is the foundation upon
which all other preventive or therapeutic measures rest.
Achieving HbA1c levels below 6.5% should be a major
priority from the moment diabetes is diagnosed. Only a
few conservative treatment options are available now for
DR; however, they are only able to slow-down progres-
sion of the disease, which sometimes takes its sight-
-threatening course despite all the available treatment.
Anti-platelet drugs (aspirin, ticlopidine, dipyridamo-
le, triflusal) delay the progression of diabetic retinopathy
in its initial stages. Large clinical trials with PKC inhibi-
tors are being carried out. Antioxidant drugs can control
oxidative stress, which modulates all other mechanisms
involved in the appearance of retinal lesions11.
Vascular growth inhibitors deserve special mention,
particularly for the prevention of proliferative diabetic
retinopathy.
It may therefore be necessary to associate several
groups of drugs that act through different mechanisms
in order to deal with the multifactorial mechanisms that
give rise to retinal lesions in diabetes mellitus12.
Patients and Methods
The study included 36 patients with PDR; middle age
65.33; 27 male, (75%), 9 female (25%); 20 patients with
DM I and 16 patients with DM II from the Department of
Ophthalmology, University Hospital Rijeka, which were
underwent vitrectomy from January 2006 to January
2008. In that period it was totally 116 patients who un-
derwent vitrectomy. All diabetic patients that suffered
from any other concomitant eye disease apart from PDR


















































Fig. 1. VEGF levels in vitreous in patients with PDR (box plot).
(or from any severe systemic inflammatory disease) were
excluded from the study.
During the surgery the sample of vitreous were col-
lected (with needle Medoject 23 G, syringe Brown 2 ccm)
and stored at the –80 °C till cytokine measurement. Con-
trols consisted of the sample of vitreous taken from ca-
davers (n=10).
Quantity of VEGF, VEGFR1 and VEGFR2 in patients
with PDR and either DM I or DM II were measured by
immunoassay (ELISA, R&D Systems, USA), as well as
vitreal samples from controls (n=10).
Results
The mean VEGF levels in the vitreous of diabetic pa-
tients (432.2 pg/mL and 147.5 pg/mL) were significantly
higher then in controls (63.26 pg/mL, p<0.005). More-
over, diabetics with PDR and diabetes mellitus type I had
significantly higher levels of VEGF (432.23 pg/mL) as
compared to those with diabetes mellitus II (147.53 pg/
mL, p<0.005) (Figure 1a and b).
Activity of VEGF is regulated by two distinct recep-
tors: VEGFR1 and VEGFR2. The mean VEGFR1 level in
the vitreous of patients with PDR and diabetes mellitus
type I (1460.41 pg/mL) was significantly higher as com-
pared to patients with PDR and diabetes mellitus type II
(641.39 pg/mL, p<0.005) (Figure 2).
Similar result was also found with the other receptor
– VEGFR2. Namely, the mean VEGFR2 level in the vitre-
ous of diabetics with PDR and diabetes mellitus I
(1054.64 pg/mL) was significantly higher than in diabet-
ics with PDR and diabetes mellitus II (448.49 pg/mL,
p<0.005) (Figure 3).
Discussion and Conclusion
In the last decade great advance has been achieved in
the research of therapeutical possibilities to block the
vascular endothelial growth factor (VEGF), particularly
in diseases of the posterior eye segment such as ARMD
(age related macular degeneration) and macular oedema
in diabetic retinopathy. The best known anti-VEGF drugs
used to treat these pathologies are: pegaptanib sodium
(Macugen), ranibizumab (Lucentis) and bevacizumab
(Avastin).
When diabetes mellitus is diagnosed, in 5% of patients
diabetic retinopathy is already present; with 80% inci-
dence in insulin-dependent patients (diabetes mellitus
type I) and 20% in insulin non-dependent diabetics (type
II). Unfortunately, 50% of patients suffering from un-
cured proliferative diabetic retinopathy will become blind
within 5 years starting from the first signs of diabetic
retinopathy.
The impact of VEGF in the progress of diabetic reti-
nopathy was first noted in 1994, when higher cytokine
values in vitreous body of patients suffering from prolife-
rative diabetic retinopathy13 have been recorded. Several
recent studies have also suggested the impact of VEGF
on ocular angiogenesis and progression of proliferative
diabetic retinopathy13–15. It is known from the literature
that several other growth factors and cytokines apart
from VEGF; such as interleukin-6, the insulin-similar
growth factor and advanced AGEs, are also included in
ocular angiogenesis.
However, there are no studies investigating the possi-
ble difference in vitreal VEGF levels depending on the
type of diabetes (I and II). Therefore, we investigated
whether vitreal VEGF values are higher in diabetic pa-
tients with PDR then in controls; and if there is any dif-
ference in VEGF level among diabetics with PDR suffer-
ing from diabetes type I or II. Our aim was to establish
which diabetes type (or maybe both) would be theoreti-
cally more susceptible to anti-VEGF therapy.
The research was conducted within 2 years’ period
(2006–2008), during which 116 patients were subjected
to vitrectomy surgery at our Department, out of which
36 diabetics with PDR were included into this study.
Samples of vitreous were collected during surgery and
VEGF (and its receptors) level was measured. Our re-
sults showed a significant increase of VEGF level in the
vitreous body of all the patients with PDR in relation to
the control group (63.26 pg/mL). This was particularly
true with the group of patients suffering from diabetes
mellitus type I (432.23 pg/mL), and slightly less (yet sta-
tistically significant!) with the group of patients with dia-
M. Merlak et al.: VEGF in Proliferative Diabetic Retinopathy, Coll. Antropol. 32 (2008) Suppl. 2: 39–43
41



















Fig. 2. VEGFR1 levels in vitreous of patients with PDR.




















Fig. 3. VEGFR2 levels in vitreous of patients with PDR.
betes mellitus type I (147.53 pg/mL). Our results, there-
fore, indicate a substantial difference in VEGF produc-
tion dependent on the type of diabetes that the patient
suffers from. Increased levels of VEGF in vitreous of pa-
tients with PDR could be explained by presence of newly
produced blood vessels, having more endothelial cells
able to produce VEGF. Moreover in the newly produced
blood vessels there are a higher number of circulating
macrophages and monocytes which infiltrate the vitre-
ous body and also produce VEGF. Thus, it is to be ex-
pected that formation of the first blood vessels will be fol-
lowed by an incessant disease exacerbation (due to VEGF
which induces ever-growing number of neo-vasculariza-
tion) and that such a behavior could be suppressed by
VEGF inhibition.
It is common knowledge that retinal pigmental epi-
thelium produces VEGF16. Lately, the role of VEGF pro-
duced from monocytes and macrophagocytes infiltrating
the vitreous body has been.investigated, indicating their
role in the progress of the proliferative diabetic retino-
pathy16–18.
In the study19 where VEGF and erythropoietin levels
in vitreous body have been measured on 73 patients with
PDR and 71 patients with non-diabetic ocular pathology,
the VEGF amount has been considerably higher with
PDR patients (VEGF of 345.0 pg/mL – 363.9 pg/mL)19.
The authors have found similar VEGF values as the ones
in our study but they did not investigate the VEGF pro-
duction related to the diabetes type, the feature that, ac-
cording to our results, also affects the VEGF level. Their
study has also revealed that the angiogenetic potential of
erythropoietin (Epo) is equivalent to the VEGF in the
vitreous body of the PDR-related patients19. Erythropoi-
etin (Epo) is a glycoprotein with angiogenetic activity
which stimulates proliferation, migration and angioge-
nesis in vitro.
Our research results have also revealed that in the
vitreous body of PDR-related patients with diabetes mel-
litus type I significantly higher levels of VEGFR1 and
VEGFR2 are present than in the vitreous body of the
PDR-related patients with diabetes mellitus type II. These
results suggest that PDR in diabetes mellitus type I is
characterized by more prominent mitogenesis, angio-
genesis and vascular permeability; therefore VEGF inhi-
bition could potentially have stronger effect in PDR-pa-
tients with diabetes mellitus type I.
Similar as in our research, in the work of Akhiro
Kakehashi et al, the measured VEGF level in the vitre-
ous body and eye liquid of diabetic patients amounted to
695.7 pg/mL; considerably higher in respect to non-dia-
betics patients (25.9 pg/mL). The immuno-histological-
-chemical analysis of VEGF, VEGF receptors, AGEs and
macrophagocytes in ocular tissues has revealed a consid-
erably higher share of all three molecules in irises and
neuro-vascular membranes of diabetic patients in re-
spect to non-diabetics patients16.
Neovascular glaucoma is another complication in PDR
patients, caused by iris rubeosis generated as the re-
sponse to retinal ischemia20. During our research period,
3 of our investigated patients with diabetic retinopathy
developed neuro-vascular glaucoma. In these patients ex-
tremely high VEGF values have been recorded (from
777.100 pg/mL to 885.681 pg/mL); the fact that can be
explained with reported data showing that apart from
retinal pigment epithelium also the neuro-vascular mem-
branes involved neuro-vascular glaucoma can produce
VEGF. This phenomenon is further confirmed by the
studies suggesting that VEGF and AGEs aggregation
plays an essential role in development of retinal and iris
neovascularization16–18. The common therapy for neovas-
cular galucoma includes pan-retinal photocoagulation
combined with medication and surgeries to suppress eye
pressure20, and our data point to a possible positive
anti-VEGF therapy role in this disease.
Other authors have also reported an increased VEGF
level in eye liquids and vitreous body in patients suffer-
ing from neovascular glaucoma20,21. Anti-VEGF drugs
can therefore lead to neovascular regression in the ante-
rior eye segment, which was already confirmed in several
studies which report rubeosis regression following the
bevacizumab intra-vitreous application20,22–24.
Considering the impact of diabetes mellitus stage on
VEGF secretion, it has been established that VEGF
tends to increase both in early and late stage of diabetic
retinopathy16,25. VEGF is attributed to induce leukocyte
adhesion to retinal capillaries causing blood-retinal bar-
rier damage and generating clinically visible bleeding in
retina and vitreous body.
Epidemiology of Diabetes Intervention and Complica-
tions Study has reported that conventional four-year
treatment tends to prevent diabetic retinopathy pro-
gression16. In the study the authors report that the find-
ings of higher VEGF and AGEs levels in neovascular
membranes, than the levels found in iris, speaks in favor
of the fact that the retina is to be attributed to be the
main VEGF source in diabetic eye. However, once the
neovascular membranes are formed, interstitial tissue
and macrophagocytes around the newly formed capillar-
ies represents the main source and stimulus of VEGF
production as seen with AMD related patients26,27. The
VEGF intra-ocular level obviously correlates essentially
to formation of new blood vessels in the patients with di-
abetic retinopathy, but also to other retinal disorders
where neovascularization is formed.
As previously mentioned, VEGF is the key factor for
angiogenesis in numerous pathological eye neovascula-
rizations, promotion of pathological inflammation, as
well as endothelial dysfunction. Considering the results
of our study, in which a significant increase of the vascu-
lar endothelial growth factor (VEGF) and its receptors
was recorded in patients affected by diabetes mellitus
(especially in those with DM type I), we believe that
there is a possibility to improve the conditions of the
aforementioned patients and to hasten their sight recov-
ery by applying anti–VEGF therapy, be it by using the al-
ready known forms of such therapy, or by discovering
new ways for blocking VEGFs (e.g. a soluble receptor
which would competitively block the free VEGF).
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EKSPRESIJA VASKULARNOG ENDOTELNOG FAKTORA RASTA U
PROLIFERATIVNOJ DIJABETI^KOJ RETINOPATIJI
S A @ E T A K
S obzirom da su vaskularizacija i vezivna proliferacija klju~ni faktori nastanka komplikacija u pacijenata sa PDR-om
cilj ovog istra`ivanja bio je utvrditi postoji li povi{enje VEGF-a u tih pacijenata i koliko ono ovisi o tipu dijabetesa. U
ispitivanje je bilo uklju~eno 20 pacijenata sa DM tip I i 16 pacijenata sa DM tip II. Njima je za vrijeme operativnog
zahvata vitrektomije uziman uzorak staklovine u kome je odre|ivana koli~ina VEGF-a i njegovih receptora (VEGFR1 i
VEGFR2) ELISA testom. U staklovinama pacijenata sa PDR-om i dijabetes melitusom tipa I prona|ena je zna~ajno
ve}a koli~ina VEGF-a i njegovih receptora (432,2 pg/mL, 1460,4 pg/mL i 1054,6 pg/mL) nego u dijabeti~ara sa PDR-om i
dijabetes melitusom tipa II (147,5 pg/mL, 641,4 pg/mL i 448,5 pg/mL) i u kontrolnoj skupini (63,26 pg/mL). Rezultati
sugeriraju da primjena anti VEGF terapije ima smisla u dijabeti~ara sa PDR-om posebno u onih sa dijabetes melitusom
tipa I.
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